Predictors for mortality in this specific category are several, including the cancer stage at the moment of diagnosis, lower breast cancer awareness among the male population as opposed to the female one [12], and important biological differences between male and female breast cancer (such as the increased prevalence of BRCA2 germline mutations or the prevalence of hormone receptor-positive cancer), which imposes the need for additional research on male breast cancer and a tailored therapeutical approach for this specific category [13]. Here, BRCA2 is linked to breast cancer.